Lawsuit Alert: Investors who lost money with ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) should contact the Shareholders Foundation

An investor, who purchased shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), filed a lawsuit over alleged violations of Federal Securities Laws by ARS Pharmaceuticals, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) have certain options and for certain investors are short and strict deadlines running. Deadline: October 5, 2026. NASDAQ: SPRY investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

San Diego, CA based ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.

On June 24, 2026, after the market closed, ARS Pharmaceuticals, Inc. published a press release allegedly announcing that ARS Pharmaceuticals did not receive expanded insurance coverage for neffy through CVS Caremark by the guided July 1, 2026 deadline, which meant that ARS Pharmaceuticals did not have expanded insurance coverage for neffy for the summer or back-to-school allergy seasons. ARS Pharmaceuticals allegedly also stated that CVS Caremark reserved its decision on the expanded insurance coverage for neffy until January 2027.

Shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) declined from $10.87 per share on June 24, 2026, to as low as $4.91 per share on August 03, 2026.

The plaintiff claims that between March 9, 2026 and June 24, 2026, the defendants made false and/or misleading statements and/or failed to disclose that the defendants knew or recklessly disregarded potential timeline issues with CVS Caremark's formulary addition and coverage decision related to neffy, that the guidance ARS Pharmaceuticals provided to investors related to the timeline for expansion of insurance coverage for neffy with CVS Caremark may be significantly shifted, impacting commercialization efforts; and that the expanded insurance coverage may not be available by the July 1 deadline, thus, ARS Pharmaceuticals would not have the expanded insurance coverage for neffy with CVS Caremark for the summer and back-to-school seasons.

Those who purchased shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.